anti-CD28 monoclonal antibody
This page covers all anti-CD28 monoclonal antibody drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD28.
Targets
Phase 3 pipeline (1)
- AML Y mg · Celltrion · Oncology
AML Y mg is an anti-CD28 monoclonal antibody that inhibits T-cell activation.
Patent intelligence
- cd28 monoclonal antibody patent landscape — aggregated cliff calendar, attackable patents, originator estates